National Comprehensive Cancer Network

About NCCN

NCCN Flash Updates™: NCCN Guidelines® & NCCN Compendium® Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Malignant Pleural Mesothelioma. These NCCN Guidelines® are currently available as Version 2.2015. 

  • Principles of Chemotherapy (MPM-B)
    • The first-line combination chemotherapy regimen of pemetrexed/cisplatin/bevacizumab followed by maintenance bevacizumab added as a treatment option for patients with unresectable malignant pleural mesothelioma. This is a category 2A recommendation.
    • Reference added: Zalcman G, Mazières J, Margery J, et al. Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial [abstract]. J Clin Oncol 2015; 33:Abstract 7500.
  • The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)

*For your reference, the previous update (Version 1.2015) to the NCCN Guidelines for Malignant Pleural Mesothelioma, published on January 27, 2015, is available at the following link: http://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf

For the complete updated versions of the NCCN Guidelines, the NCCN Compendium®, and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org.

To access the NCCN Biomarkers Compendium®, please visit NCCN.org/biomarkers.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients.

Free NCCN Guidelines apps iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps

 About NCCN Flash Updates™ 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)

275 Commerce Drive, Suite 300

Fort Washington, PA 19034

Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2015 National Comprehensive Cancer Network. All Rights Reserved.